EXHIBIT 99.1
                                                                    ------------

FOR IMMEDIATE RELEASE
---------------------

Contact, at (781) 861-8444:
         Michael W. Rogers                           William B. Boni
         Exec. VP and Chief Financial Officer        VP, Corp. Communications

              INDEVUS PHARMACEUTICALS, INC., FORMERLY INTERNEURON,

                           TO BEGIN TRADING ON NASDAQ

LEXINGTON, MA, April 2, 2002 - Indevus Pharmaceuticals, Inc., formerly
Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC), today announced that the
Company will trade on the Nasdaq Stock Market under the new ticker symbol, IDEV,
beginning tomorrow, April 3, 2002. Interneuron's shareholders approved the
corporate name change to Indevus at the annual meeting of shareholders held
today.

"The old name, Interneuron, reflected our origins as a neurosciences company,
while the new name better describes our mission of product acquisition on an
international basis and our core expertise in product development," said Glenn
L. Cooper, M.D., chairman, president and chief executive officer of Indevus. "In
addition, our current product portfolio includes opportunities in multiple,
diverse therapeutic areas. This evolution away from a neurological focus has
taken place during the past several years with the in-licensing and development
of product candidates for indications that include anxiety disorders, overactive
bladder, inflammatory bowel disease and the prevention of HIV transmission.

"Our shareholders can expect the Indevus pipeline to grow in the years ahead
with the acquisition of additional promising opportunities in multiple
therapeutic areas and the advancement of these product candidates through
clinical development," said Dr. Cooper.

The Company's lead products under development include: trospium, in Phase III
clinical testing for overactive bladder; pagoclone, in Phase III clinical
testing for panic disorder and Phase II testing for generalized anxiety disorder
being conducted by Pfizer Inc.; PRO 2000, in Phase II clinical testing for the
prevention of infection by HIV and other sexually transmitted pathogens; and
dersalazine, in Phase I clinical testing for inflammatory bowel disease. The
Company's partners include biopharmaceutical, regional pharmaceutical and
multi-national pharmaceutical firms, as well as academic and government
institutions.

                                    - MORE -

Page 1 of 2



                                      - 2 -

Indevus will introduce a new web site, http://www.indevus.com, on April 3, 2002.
Investors and individuals interested in further information about the Company,
its products and its partners are encouraged to visit the site.

Indevus Pharmaceuticals is engaged in the development and commercialization of a
portfolio of products and product candidates, including multiple compounds in
late-stage clinical development.

Except for the descriptions of historical facts contained herein, this press
release contains forward-looking statements that involve risks and uncertainties
that could cause the Company's actual results and financial condition to differ
materially from those anticipated by the forward looking statements. These risks
and uncertainties are set forth in the Company's filings under the Securities
Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and
elsewhere, and include, but are not limited to: uncertainties relating to
clinical trials, regulatory approval and commercialization of our products; the
early stage of products under development; need for additional funds and
corporate partners; history of operating losses and expectation of future
losses; product liability and insurance uncertainties; risks relating to the
Redux-related litigation; dependence on third parties for manufacturing and
marketing; competition; risks associated with contractual arrangements; limited
patents and proprietary rights; and other risks.

                                       ###